OrthoPediatrics Q3 2026 net loss narrows 50% to $5.93 million
- OrthoPediatrics’ third-quarter 2026 net loss narrowed 50% year-over-year to $5.93 million.
- Revenue rose 19% year-over-year to $72.7 million, driven primarily by global Trauma and Deformity and OPSB products.
- Full market releases included the 3P Pediatric Plating Platform Hip System and PediHip Rigid Brace.
- Full-year 2026 revenue guidance increased to $270 million–$273 million, representing growth of 14%–16% over 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271605PRIMZONEFULLFEED9854233) on October 27, 2026, and is solely responsible for the information contained therein.